Ten Developments in the Use of Biologicals for Systemic Lupus Erythematosus
- First Online:
- Cite this article as:
- Wallace, D.J. Curr Rheumatol Rep (2013) 15: 337. doi:10.1007/s11926-013-0337-z
Belimumab has recently been approved, and several other types of biological therapy with different mechanisms of action are currently in phase II and III studies. This review puts these approaches in context, emphasizing mechanistic categories and clinical trial designs. Most of the promising approaches involve B cell depletion or modulation. Post-approval experience with belimumab is critically reviewed.